Troglitazone과 COX-2 억제제 병합 투여가 아교모세포종세포의 세포자멸사에 미치는 영향

• Published in: Journal of pathology and translational medicine pp. 1 - 6
• Main Authors: 김경열, 박민영, 박호성, 장규윤, 문우성, 이동근, 강명재
• Format: Journal Article
• Language: Korean
• Published: 대한병리학회 01-02-2007
• Subjects: 병리학
• ISSN: 2383-7837; 2383-7845

Background : The use of troglitazone (a PPARγ ligand) and COX-2 inhibitor have been intensively
studied for inhibition of tumor growth in cancer treatment, but the anti-tumor effect with
a combination of these agents for cancer has not yet been studied. The aim of this study was
to determine if low concentrations of troglitazone with COX-2 inhibitor in combination would
cause significant cytotoxicity in glioma cells. Methods : The effects of co-treatment with troglitazone
and COX-2 inhibitor on cell growth and apoptosis were assessed by use of trypan blue
exclusion and a DNA fragmentation assay. A western blot was used to analyze the apoptotic
signaling for the expression of bcl-2, bax, PARP and p21 proteins. Results : A low dose of
troglitazone (5 μM) and COX-2 inhibitor (5 μM) strongly enhanced the cell growth inhibition
and apoptosis in glioma cells when compared to a low dose of each drug alone. Western blotting
analysis showed a decreased expression of bcl-2 and PARP proteins. In contrast, the
bax protein level was increased. Conclusions : The combination of troglitazone and COX-2
inhibitor in a low dose elicits synergistic cytotoxicity in glioma cells. Our study also demonstrates
that down regulation of bcl-2, fragmentation of PARP protein and increased expression of bax
protein were accompanied by co-treatment with troglitazone and the COX-2 inhibitor. KCI Citation Count: 0